Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.
Bernadette Anna Maria Heemskerk-GerritsenAntoinette HollestelleChristi J van AsperenIrma van den BeekWillemien J van DrielKlaartje van EngelenEncarna B Gómez GarciaJoanne A de HulluMarco J KoudijsMarian J E MouritsMaartje J HooningIngrid A BoerePublished in: PloS one (2022)
For epithelial ovarian cancer patients who received chemotherapy, we confirmed survival benefit for BRCA1 and BRCA2 germline pathogenic variant carriers. This may indicate higher sensitivity to chemotherapy, both in first line treatment and in the recurrent setting. The observed benefit appears to be limited to a relatively short period after epithelial ovarian cancer diagnosis.